Indivior Pharmaceuticals, Inc. (INDV)
🔔 Watch stock
symbol.quality_heading
The business works in principle, but one material question is open. As long as it stays open, our findings do not carry a quality verdict.
Open questions rather than a substance risk: the company earns real money — $210 million of net income in 2025, $89 million in the first quarter of 2026, a gross margin around 80 percent and the Department of Justice settlement paid in full — but 69 percent of revenue (73 percent in the first quarter of 2026) rides on a single depot injection, both pipeline candidates were dropped in that same quarter, and stockholders' equity stands at minus $144 million, so there is no asset cushion behind that one product. What answers the open part shows up in every quarterly report (10-Q): SUBLOCADE growth (most recently plus 32 percent), news of generic or branded challenges to the injection, and the Medicaid trajectory after the OBBBA act — if none of the three tips over, the machine stays intact. The rating says nothing about the entry price — that is what the metrics scanners answer. The decision is yours.
symbol.quality_note
Indivior treats opioid addiction — and is painting the highest high-water mark in its history: 27 hits in our in-house stock scanner, from the Weinstein stage-2 uptrend to the RS leaders, after a gain of 197 percent in twelve months (momentum run of July 17, 2026). We read the first annual report (10-K) since the move from London to Virginia and the quarterly report (10-Q) as of March 31, 2026: a record $210 million profit for 2025, a fully paid Department of Justice settlement, a $400 million buyback program — but also 69 percent of revenue riding on a single depot injection, a pipeline that died twice in one quarter, three wholesalers billing more than half the revenue, and stockholders' equity below zero. Not investment advice — just a look below the waterline of a stock trading at its high-water mark.
Read the analysis
Stock Watch
This analysis is as of July 17, 2026. Stock Watch will tell you what's changed at INDV since then.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 28 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 40.00 $ — 92% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AI Rating
NeutralGeprüft am 17.07.2026: In den ausgewerteten SEC-Berichten von Indivior (CIK 1625297; SEC-Titel seit Januar 2026 „Indivior Pharmaceuticals, Inc.“, vorher Indivior PLC — Redomestizierung UK→US per Scheme of Arrangement, wirksam nach Börsenschluss am 23.01.2026, gegen EDGAR-formerNames verifiziert) findet sich kein wesentlicher KI-Bezug zum Geschäftsmodell. Ausgewertet wurden die letzten 4×10-Q und 2×10-K (die Firma berichtet erst seit März 2025 als US-Domestic-Filer; davor 20-F/6-K als Foreign Private Issuer). Befund: Der 10-K für 2025 enthält ausschließlich einen generischen Risikofaktor zu KI als Datenschutz-/Sicherheitsthema („Artificial intelligence presents risks and challenges that can impact our business including by posing security risks to our confidential information, proprietary information, and personal data“ — übersetzt: „Künstliche Intelligenz birgt Risiken und Herausforderungen, die unser Geschäft beeinträchtigen können, unter anderem durch Sicherheitsrisiken für unsere vertraulichen Informationen, unser geistiges Eigentum und personenbezogene Daten“) sowie den Hinweis, man könne generative KI-Werkzeuge für geprüfte Anwendungsfälle einführen und Anbieter könnten solche Werkzeuge unangekündigt einsetzen („We may adopt and integrate generative artificial intelligence tools into our systems for specific use cases reviewed by legal and information security“ — übersetzt: „Wir könnten generative KI-Werkzeuge für bestimmte, von Rechtsabteilung und Informationssicherheit geprüfte Anwendungsfälle in unsere Systeme integrieren“). Das ist Standard-Boilerplate ohne konkreten Bezug zum eigenen Geschäftsmodell (Pharmazeutika gegen Opioidabhängigkeit) — nach Kriterienkatalog weder „verkauft“ noch „nutzt“ (kein belegter operativer Einsatz, keine KI-Umsatzquelle) noch „bedroht“ (kein konkretes Geschäftsmodell-Risiko). Der 10-K für 2024 und die 10-Q zum 31.03.2025, 30.06.2025, 30.09.2025 und 31.03.2026 enthalten keinerlei belastbare KI-Treffer (nur Scheintreffer wie „HIV/AIDS“). Nach dem Kriterienkatalog bleibt es bei „neutral“.
View the full file — quotes, sources, reviewed filings
Filings Reviewed: 10-Q 2026-04-30 · 10-Q 2025-10-30 · 10-Q 2025-07-31 · 10-Q 2025-05-01 · 10-K 2026-02-26 · 10-K 2025-03-03
Rated on July 17, 2026 · How the Rating Is Built
Growth Score
4 of 10 Weak growthTen checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years 11.2% failed
- More than 10% revenue growth is expected for the coming year 2.3% failed
- Share count grows by less than 3% a year -2.7% passed
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") -3.2% failed
- Gross margin at 40% or higher and without meaningful erosion 80.2% failed
- Goodwill from acquisitions does not grow faster than revenue 0.2% passed
- Net debt below twice EBITDA 0.5 x EBITDA passed
- Operating cash flow covers the profits of the last three years -374 m failed
- Return on capital at 15% or higher, or up versus two years ago 91.4% passed
- Insiders hold at least 10% or are net buyers 4.8% failed
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 27.1% above the current price.
- Consensus
- Strong Sell
- Analyst Ratings
- 7
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 3.85 | 3.63 – 4.05 | 1,260 | 54.2% | 5 |
| 12/31/2027 | 4.17 | 3.91 – 4.32 | 1,312 | 8.1% | 5 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
- Expected Earnings per Share
- 0.97 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | 0.46 | 21.10 | 299 | 2.00 | 19.70 | -6 | -22 |
| 2025: Q1 | 0.38 | -13.60 | 266 | -6.30 | 17.70 | 75 | 70 |
| 2025: Q2 | 0.15 | – | 302 | 1.00 | 6.00 | 166 | 148 |
| 2025: Q3 | 0.33 | 987.10 | 314 | 2.30 | 13.40 | -39 | -59 |
| 2025: Q4 | 0.82 | 77.10 | 358 | 19.70 | 28.50 | -221 | -245 |
| 2026: Q1 | 0.69 | 81.60 | 317 | 19.20 | 28.10 | -9 | -29 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 969 | 338 | 32 | 0.22 | 373 | -295 | 1,209 |
| 2017 | 1,148 | 423 | 61 | 0.41 | 310 | -203 | 1,444 |
| 2018 | 960 | 317 | 263 | 1.75 | 289 | 66 | 1,547 |
| 2019 | 785 | 178 | 134 | 0.89 | 151 | 209 | 1,652 |
| 2020 | 647 | -156 | -148 | -1.01 | -193 | 82 | 1,531 |
| 2021 | 791 | 213 | 205 | 1.33 | 353 | 203 | 1,832 |
| 2022 | 901 | -81 | -44 | -0.32 | -4 | 51 | 1,779 |
| 2023 | 1,093 | -156 | -129 | -0.91 | -300 | -191 | 1,765 |
| 2024 | 1,188 | 32 | 2 | 0.02 | 36 | -348 | 1,319 |
| 2025 | 1,239 | 265 | 210 | 1.64 | -27 | -98 | 1,204 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
Assessment: Opportunities & Risks
SUBLOCADE grew 13 percent to $856 million in 2025 and 32 percent in the first quarter of 2026; the company swung from a $126 million loss (2023) to $210 million in net income (2025) and $89 million in the quarter — at a gross margin around 80 percent (10-K 2025, 10-Q as of 03/31/2026).
69 percent of 2025 revenue (Q1 2026: 73 percent) hangs on SUBLOCADE, and in the first quarter of 2026 both pipeline candidates were dropped: INDV-2000 missed its primary endpoint, INDV-6001 will not enter Phase 3 (10-Q, "Pipeline Updates"). The risk factors also flag generics and branded competition against SUBLOCADE and the film.
Three U.S. wholesalers accounted for 51 percent of 2025 revenue (the largest for 20 percent), and the 10-K names Medicaid cuts under the OBBBA budget act as a concrete risk to coverage of higher-cost OUD treatments — which is precisely the depot injection.
Legacy legal cases cleared (the $295 million DOJ prepayment in November 2025, no further obligation), the interest bill cut via a 0.625 percent convertible, a $400 million buyback running — but stockholders' equity stands at minus $144 million, cash fell to $175 million, and the note starts to dilute above $41.66 (10-Q as of 03/31/2026).
A stage-2 uptrend, relative strength 90, 27 scanner hits and a 197 percent twelve-month gain meet a trailing P/E around 21 and about eleven times 2026 estimates (momentum run of July 17, 2026) — moderate for the growth, but with no asset cushion underneath, and with insider buying as a notable counterpoint (seven buys, zero sells).
Indivior is delivering the best version of itself: record profit, paid-off legal legacy, a core product with a medical advantage and category tailwind, plus buybacks and insider buying. At the same time, after the double pipeline failure in the first quarter of 2026, the company is economically a one-product house with three wholesalers as half its customer base, Washington as its most important payer and stockholders' equity below zero — all of its resilience lies in future SUBLOCADE cash flow. Whoever holds the stock holds a focused cash machine with concentration risk in every dimension. Not investment advice.
- INDV reached the research list via the momentum run of July 17, 2026 with 27 scanner hits (including Stan Weinstein stage 2, RS leaders ≥90, Minervini trend criteria, power trend, net insider buying) — identity verified against SEC EDGAR: SEC title since January 2026 is "Indivior Pharmaceuticals, Inc." (formerly Indivior PLC), CIK 1625297.
- Scanner metrics (P/E, P/S, Piotroski, Altman Z, fundamental grade) use trailing twelve-month figures; the DOJ prepayment (November 2025) depresses trailing operating cash flow, and the $18 million loss on debt extinguishment weighs on the first quarter of 2026.
- Price and valuation figures are dated to the momentum run of July 17, 2026 (about $41 per share, about $4.7 billion market value); analyses are evergreen, daily prices are not a buy argument.
About the Company
Indivior Pharmaceuticals, Inc. befasst sich gemeinsam mit ihren Tochtergesellschaften mit Entwicklung, Herstellung und Verkauf von buprenorphinbasierten verschreibungspflichtigen Medikamenten zur Behandlung von Opioidabhängigkeit und damit verbundenen Störungen in den USA, Europa, Kanada, Australien und international.
| Employees | 827 |
|---|---|
| Headquarters | North Chesterfield, VA |
| Address | 10710 Midlothian Turnpike, 23235 North Chesterfield, United States |
| Phone | 804 379 1040 |
| Website | indivior.com |
| IPO Date | 29. Dec 2014 |
| ISIN | GB00BN4HT335 |
| Stock Split | 1:5 on 10/10/2022 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Joseph J. Ciaffoni | CEO & Director | 1971 |
| Ryan Preblick | Chief Financial Officer | 1976 |
| Christian Heidbreder | Chief Scientific Officer | 1963 |
| Jeffrey W. Burris J.D. | Chief Legal Officer | 1972 |
| Patrick a. Barry | Chief Commercial Officer | 1968 |
| Jason Thompson | Vice President of Investor Relations | – |
| Kevin L. Espinoza | Chief Integrity & Compliance Officer | – |
| Angela Colon-Mahoney M.S. | Chief Human Resources Officer | 1976 |
| Vanessa Procter | Executive Vice President of Corporate Affairs | – |
| Alice G. Givens | Company Secretary | 1974 |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 10. Jul 2026 | Heidbreder Christian | Chief Scientific Officer | Sell | 18,586 | 41.14 | 764,628 |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.
View all insider transactions →Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.